Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Medical Oncology|September 2, 2022
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancerElyssa Denault, Erika Nakajima, Vivek Naranbhai, et al.
JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.
Cancer|November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistanceTiago Goncalves, Dagoberto Pulido, Carmen M Perrino, et al.
Ebiomedicine|June 27, 2025
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerMaxwell R Lloyd, Rosario Chica-Parrado, Caroline M Weipert, et al.
Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 24, 2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter ExperienceSeth A Wander, Hyo S Han, Mark L Zangardi, et al.
The Lancet. Oncology|April 30, 2026
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trialSeth A Wander, Maxwell R Lloyd, Jennifer C Keenan, et al.
JCO Precision Oncology|May 4, 2023
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor ProgressionJamie O Brett, Taronish D Dubash, Gabriela N Johnson, et al.
Cancer Discovery|May 15, 2020
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast CancerSeth A Wander, Ofir Cohen, Xueqian Gong, et al.
Pageof 8